Sweden-based biotechnology company TIRmed Pharma, which develops immunomodulatory therapies for autoimmune skin diseases, announced on Tuesday that it has entered a manufacturing collaboration with Swiss biotechnology company Bachem Holding AG (SWX: BANB).

The agreement covers process development and production of TIR-01, the active pharmaceutical ingredient for TIRmed Pharma's next-generation treatment for atopic dermatitis.

TIRmed Pharma's therapy is designed to target underlying disease mechanisms and has shown sustained relief of up to 15 months in preclinical studies following a two-week topical application routine.

Bachem will support GMP development and manufacturing of the oligonucleotide-based substance to ensure stability, consistency, and regulatory readiness ahead of clinical trials.

TIRmed Pharma said the collaboration strengthens its efforts to bring its candidate drug into the clinic.